Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Review Article

Advances in the Development of Carbonic Anhydrase Inhibitors as New Antiprotozoal Agents

In Press, (this is not the final "Version of Record"). Available online 31 October, 2023
Author(s): Eyra Ortiz-Perez, Lenci K. Vazquez-Jimenez, Alma D. Paz-Gonzalez, Timoteo Delgado-Maldonado, Alonzo González González, Carlos Gaona-Lopez, Antonio Moreno-Herrera, karina Vazquez and Gildardo Rivera*
Published on: 31 October, 2023

DOI: 10.2174/0109298673249553231018070920

Price: $95

Abstract

Background: Parasitic diseases are a public health problem despite the existence of drugs for their treatment. These treatments have variable efficacy and, in some cases, serious adverse effects. There has been interest in the enzyme carbonic anhydrase (CA) in the last two decades since it is essential in the life cycle of various parasites due to its important participation in processes such as pyrimidine synthesis, HCO3- transport across cell membranes, and the maintenance of intracellular pH and ion transport (Na+, K+, and H+), among others.

Objective: In this review, CA was analyzed as a pharmacological target in etiological agents of malaria, American trypanosomiasis, leishmaniasis, amoebiasis, and trichomoniasis. The CA inhibitors´ design, binding mode, and structure-activity relationship are also discussed.

Conclusion: According to this review, advances in discovering compounds with potent inhibitory activity suggest that CA is a candidate for developing new antiprotozoal agents.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy